Table 1.

Main clinical and demographic characteristics of patients included in the study

	Total sample (n = 186)	Blepharospasm (n = 65)	Cervical dystonia (n = 46)	Hemifacial spasm (n = 40)	Oromandibular dystonia (n = 5)	Focal dystonia (n = 16)	Sialorrhea (n = 14)
Sex
Female	115 (61.8%)	46 (70.8%)	27 (58.7%)	28 (70%)	3 (60%)	8 (50%)	3 (21.4%)
Male	71 (38.2%)	19 (29.2%)	19 (41.3%)	12 (30%)	2 (40%)	8 (50%)	11 (78.6%)
Age
	68.2 ± 15 (20–96)	73.7 ± 12.2 (26–96)	61 ± 15.1 (20–88)	72.6 ± 13.3 (43–91)	55.9 ± 8 (49–68)	54.7 ± 17.6 (24–83)	74.9 ± 8.1 (56–85)
Years of treatment with BoNT
	8.7 ± 7.2 (1–33)	9.1 ± 6.3 (1–31)	10 ± 7.4 (1–27)	11.4 ± 8.9 (1–33)	5.4 ± 2 (2–7)	4.1 ± 3.2 (1–14)	2.7 ± 1.4 (1–5)
Type of BoNT
OnaBoNTA	98 (52.7%)	52 (80%)	1 (2.2%)	32 (80%)	1 (20%)	0	12 (85.7%)
IncoBoNTA	31 (16.7%)	13 (20%)	6 (13%)	7 (17.5%)	2 (40%)	1 (6.2%)	2 (14.3%)
AboBoNTA	57 (30.6%)	0	39 (84.8%)	1 (2.5%)	2 (40%)	15 (93.8%)	0
Dose of BoNT (U)
	63 ± 55.4 (2.5–500)	45 ± 19.7 (10–95)	109 ± 46.9 (33.3–266.7)	31.1 ± 18.8 (7.5–65)	59 ± 55.3 (6.7–133.3)	78.2 ± 62 (16.7–266.7)	50.7 ± 19 (20–90)

Data are reported as mean ± standard deviation (range) or number of patients (percentage)

BoNT botulinum toxin